N
21.32
1.03 (5.08%)
| Previous Close | 20.29 |
| Open | 20.29 |
| Volume | 1,226,374 |
| Avg. Volume (3M) | 993,977 |
| Market Cap | 2,343,387,648 |
| Price / Sales | 3.59 |
| Price / Book | 6.16 |
| 52 Weeks Range | |
| Earnings Date | 27 Feb 2025 |
| Profit Margin | -27.86% |
| Operating Margin (TTM) | -38.66% |
| Diluted EPS (TTM) | -1.56 |
| Quarterly Revenue Growth (YOY) | 20.50% |
| Total Debt/Equity (MRQ) | 189.72% |
| Current Ratio (MRQ) | 1.46 |
| Operating Cash Flow (TTM) | -26.37 M |
| Levered Free Cash Flow (TTM) | 9.29 M |
| Return on Assets (TTM) | -8.77% |
| Return on Equity (TTM) | -46.67% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | NovoCure Limited | Mixed | Bullish |
AIStockmoo Score
0.2
| Analyst Consensus | 2.0 |
| Insider Activity | 0.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Average | 0.20 |
|
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
| % Held by Insiders | 9.46% |
| % Held by Institutions | 84.82% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 42.00 (Piper Sandler, 97.00%) | Buy |
| Median | 40.00 (87.62%) | |
| Low | 38.00 (HC Wainwright & Co., 78.24%) | Buy |
| Average | 40.00 (87.62%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 29.82 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 14 Jan 2025 | 38.00 (78.24%) | Buy | 26.23 |
| Piper Sandler | 13 Dec 2024 | 42.00 (97.00%) | Buy | 33.41 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BEN ARYE BARAK | 18.19 | - | 54,975 | 999,995 |
| BRACKMANN CHRISTOPH | 18.19 | - | 54,975 | 999,995 |
| CORDOVA ASHLEY | 18.19 | 18.90 | 135,634 | 2,453,072 |
| LEONARD FRANK X | 18.19 | 18.90 | 37,412 | 664,774 |
| LEUPIN NICOLAS | 18.19 | 19.23 | 53,984 | 980,938 |
| PARAVASTHU MUKUND | 18.19 | 18.90 | 52,711 | 956,722 |
| PURI MICHAL NATH | 18.19 | 19.23 | 53,588 | 973,323 |
| WEINBERG URI | 18.19 | 18.74 | 50,070 | 906,634 |
| Aggregate Net Quantity | 493,349 | |||
| Aggregate Net Value ($) | 8,935,454 | |||
| Aggregate Avg. Buy ($) | 18.19 | |||
| Aggregate Avg. Sell ($) | 18.93 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PURI MICHAL NATH | Officer | 04 Mar 2025 | Acquired (+) | 54,975 | 18.19 | 999,995 |
| BEN ARYE BARAK | Officer | 04 Mar 2025 | Acquired (+) | 54,975 | 18.19 | 999,995 |
| WEINBERG URI | Officer | 04 Mar 2025 | Acquired (+) | 54,975 | 18.19 | 999,995 |
| LEONARD FRANK X | Officer | 04 Mar 2025 | Acquired (+) | 54,975 | 18.19 | 999,995 |
| PARAVASTHU MUKUND | Officer | 04 Mar 2025 | Acquired (+) | 54,975 | 18.19 | 999,995 |
| CORDOVA ASHLEY | Officer | 04 Mar 2025 | Acquired (+) | 151,181 | 18.19 | 2,749,982 |
| LEUPIN NICOLAS | Officer | 04 Mar 2025 | Acquired (+) | 54,975 | 18.19 | 999,995 |
| BRACKMANN CHRISTOPH | Officer | 04 Mar 2025 | Acquired (+) | 54,975 | 18.19 | 999,995 |
| PARAVASTHU MUKUND | Officer | 03 Mar 2025 | Sell (-) | 250 | 18.41 | 4,603 |
| CORDOVA ASHLEY | Officer | 03 Mar 2025 | Sell (-) | 2,053 | 18.41 | 37,796 |
| LEONARD FRANK X | Officer | 03 Mar 2025 | Sell (-) | 2,527 | 18.41 | 46,522 |
| WEINBERG URI | Officer | 03 Mar 2025 | Sell (-) | 268 | 18.41 | 4,934 |
| PARAVASTHU MUKUND | Officer | 28 Feb 2025 | Sell (-) | 368 | 19.07 | 7,018 |
| CORDOVA ASHLEY | Officer | 28 Feb 2025 | Sell (-) | 2,341 | 19.07 | 44,643 |
| LEONARD FRANK X | Officer | 28 Feb 2025 | Sell (-) | 2,770 | 19.07 | 52,824 |
| WEINBERG URI | Officer | 28 Feb 2025 | Sell (-) | 4,637 | 19.07 | 88,428 |
| PARAVASTHU MUKUND | Officer | 27 Feb 2025 | Sell (-) | 1,646 | 19.23 | 31,653 |
| CORDOVA ASHLEY | Officer | 27 Feb 2025 | Sell (-) | 11,153 | 19.23 | 214,472 |
| LEONARD FRANK X | Officer | 27 Feb 2025 | Sell (-) | 12,266 | 19.23 | 235,875 |
| PURI MICHAL NATH | Officer | 27 Feb 2025 | Sell (-) | 1,387 | 19.23 | 26,672 |
| LEUPIN NICOLAS | Officer | 27 Feb 2025 | Sell (-) | 991 | 19.23 | 19,057 |
| Show more | ||||||
| Date | Type | Details |
|---|---|---|
| 04 Mar 2025 | Announcement | Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference |
| 27 Feb 2025 | Announcement | Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update |
| 22 Jan 2025 | Announcement | Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland |
| 13 Jan 2025 | Announcement | Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update |
| 03 Jan 2025 | Announcement | Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |